Diagnostic accuracy of antibiograms in predicting the risk of antimicrobial resistance for individual patients

Shinya Hasegawa, Jonas Church, Eli Perencevich, Michihiko Goto
{"title":"Diagnostic accuracy of antibiograms in predicting the risk of antimicrobial resistance for individual patients","authors":"Shinya Hasegawa, Jonas Church, Eli Perencevich, Michihiko Goto","doi":"10.1017/ash.2023.276","DOIUrl":null,"url":null,"abstract":"Background: Many clinical guidelines recommend that clinicians should use antibiograms to decide on empiric antimicrobial therapy. However, antibiograms aggregate epidemiologic data without consideration for any other factors that may affect the risk of antimicrobial resistance (AMR), and little is known about an antibiogram’s reliability in predicting antimicrobial susceptibility. We assessed the diagnostic accuracy of antibiograms as a prediction tool for E. coli clinical isolates in predicting the risk of AMR for individual patients. Methods: We extracted microbiologic and patient-level data from the nationwide clinical data warehouse of the Veterans Health Administration (VHA). We assessed the diagnostic accuracy of the antibiogram for 3 commonly used antimicrobial classes for E. coli : ceftriaxone, fluoroquinolones, and trimethoprim-sulfamethoxazole. First, we retrospectively generated facility-level antibiograms for all VHA facilities from 2000 to 2019 using all clinical culture specimens positive for E. coli , according to the latest Clinical & Laboratory Standards Institute guideline. Second, we created a patient-level data set by including only patients who did not have a positive culture for E. coli in the preceding 12 months. Then we assessed the diagnostic accuracy of an antibiogram for E. coli to predict resistance for the isolates in the following calendar year, using logistic regression models with percentages in the antibiogram as dependent variables. We also set 5 stepwise thresholds at 80%, 85%, 90%, 95%, and 98%, and we calculated sensitivity, specificity, and accuracy for each antimicrobial. Results: Among 127 VHA hospitals, 1,484,038 isolates from 704,779 patients were available for analysis. The area under the ROC curve (AU-ROC) was 0.686 for ceftriaxone, 0.637 for fluoroquinolones, and 0.578 for trimethoprim-sulfamethoxazole, suggesting their relatively poor prediction performances (Fig. 1). The sensitivity and specificity of the antibiogram widely varied by antimicrobial groups and thresholds, with substantial trade-offs. Along with AU-ROC, these metrics suggest poor prediction performances when antibiograms are used as the sole prediction tool (Fig. 2). Conclusions: Antibiograms for E. coli have poor performances in predicting the risk of AMR for individual patients when they are used as a sole tool, and their contribution to the clinical decision making may be limited. Clinicians should also consider other clinical and epidemiologic data when interpreting antibiograms, and guideline statements that suggest antibiogram as a valuable tool for decision making in empiric therapy may need to be reconsidered. Further studies are needed to evaluate the contribution of antibiograms when combined with other patient-level factors. Disclosures: None","PeriodicalId":7953,"journal":{"name":"Antimicrobial Stewardship & Healthcare Epidemiology","volume":"3 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Stewardship & Healthcare Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/ash.2023.276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Many clinical guidelines recommend that clinicians should use antibiograms to decide on empiric antimicrobial therapy. However, antibiograms aggregate epidemiologic data without consideration for any other factors that may affect the risk of antimicrobial resistance (AMR), and little is known about an antibiogram’s reliability in predicting antimicrobial susceptibility. We assessed the diagnostic accuracy of antibiograms as a prediction tool for E. coli clinical isolates in predicting the risk of AMR for individual patients. Methods: We extracted microbiologic and patient-level data from the nationwide clinical data warehouse of the Veterans Health Administration (VHA). We assessed the diagnostic accuracy of the antibiogram for 3 commonly used antimicrobial classes for E. coli : ceftriaxone, fluoroquinolones, and trimethoprim-sulfamethoxazole. First, we retrospectively generated facility-level antibiograms for all VHA facilities from 2000 to 2019 using all clinical culture specimens positive for E. coli , according to the latest Clinical & Laboratory Standards Institute guideline. Second, we created a patient-level data set by including only patients who did not have a positive culture for E. coli in the preceding 12 months. Then we assessed the diagnostic accuracy of an antibiogram for E. coli to predict resistance for the isolates in the following calendar year, using logistic regression models with percentages in the antibiogram as dependent variables. We also set 5 stepwise thresholds at 80%, 85%, 90%, 95%, and 98%, and we calculated sensitivity, specificity, and accuracy for each antimicrobial. Results: Among 127 VHA hospitals, 1,484,038 isolates from 704,779 patients were available for analysis. The area under the ROC curve (AU-ROC) was 0.686 for ceftriaxone, 0.637 for fluoroquinolones, and 0.578 for trimethoprim-sulfamethoxazole, suggesting their relatively poor prediction performances (Fig. 1). The sensitivity and specificity of the antibiogram widely varied by antimicrobial groups and thresholds, with substantial trade-offs. Along with AU-ROC, these metrics suggest poor prediction performances when antibiograms are used as the sole prediction tool (Fig. 2). Conclusions: Antibiograms for E. coli have poor performances in predicting the risk of AMR for individual patients when they are used as a sole tool, and their contribution to the clinical decision making may be limited. Clinicians should also consider other clinical and epidemiologic data when interpreting antibiograms, and guideline statements that suggest antibiogram as a valuable tool for decision making in empiric therapy may need to be reconsidered. Further studies are needed to evaluate the contribution of antibiograms when combined with other patient-level factors. Disclosures: None
抗生素谱在预测个体患者抗菌素耐药性风险中的诊断准确性
背景:许多临床指南建议临床医生应使用抗生素图来决定经验性抗菌药物治疗。然而,抗生素谱汇总了流行病学数据,而没有考虑任何其他可能影响抗菌素耐药性风险的因素,而且我们对抗生素谱预测抗菌素敏感性的可靠性知之甚少。我们评估了抗生素谱作为大肠杆菌临床分离株预测个体患者AMR风险的预测工具的诊断准确性。方法:我们从退伍军人健康管理局(VHA)的全国临床数据仓库中提取微生物学和患者水平的数据。我们评估了大肠杆菌3种常用抗菌药物类别的抗生素谱诊断准确性:头孢曲松、氟喹诺酮类和甲氧苄啶-磺胺甲恶唑。首先,根据最新的clinical &实验室标准协会指南。其次,我们创建了一个患者水平的数据集,仅包括在过去12个月内大肠杆菌培养未呈阳性的患者。然后,我们使用逻辑回归模型,以抗生素谱中的百分比作为因变量,评估大肠杆菌抗生素谱的诊断准确性,以预测下一个日历年分离株的耐药性。我们还设置了5个逐步阈值,分别为80%、85%、90%、95%和98%,并计算了每种抗菌药物的敏感性、特异性和准确性。结果:在127家VHA医院中,从704779例患者中分离出1484038株用于分析。头孢曲松的ROC曲线下面积(AU-ROC)为0.686,氟喹诺酮类药物为0.637,甲氧苄啶-磺胺甲恶唑为0.578,表明它们的预测性能相对较差(图1)。抗生素谱的敏感性和特异性因抗菌素组和阈值而异,存在大量权衡。与AU-ROC一样,这些指标表明,当抗生素谱作为唯一的预测工具时,这些指标的预测效果很差(图2)。结论:当抗生素谱作为唯一的工具使用时,大肠杆菌的抗生素谱在预测个体患者AMR风险方面的表现很差,它们对临床决策的贡献可能有限。临床医生在解释抗生素图时还应考虑其他临床和流行病学数据,而建议抗生素图作为经验性治疗决策的有价值工具的指南声明可能需要重新考虑。需要进一步的研究来评估抗生素谱与其他患者水平因素结合时的作用。披露:没有
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信